Navigation Links
InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
Date:2/3/2009

dy, the compelling safety and tolerability profile observed in CAPACITY, together with the urgent unmet medical need for new medicines to treat IPF strongly support our decision to move forward with our NDA and an MAA submissions for pirfenidone as soon as possible. IPF is a disease that is more lethal than almost every form of cancer, affects almost 250,000 Americans and Europeans combined, and for which there are no medicines approved for their treatment."

Primary Endpoint Results

The primary endpoint of both CAPACITY studies was change in percent predicted Forced Vital Capacity (FVC) after 72 weeks of treatment, evaluated with a nonparametric rank ANCOVA. In the CAPACITY 2 study, the primary endpoint was met (p = 0.001). In CAPACITY 1, the primary endpoint was not met (p= 0.501). An exploratory analysis of pooled primary endpoint data from both studies using the pre-specified primary endpoint test statistic from a nonparametric rank ANCOVA resulted in a P value of 0.005.

A pre-specified repeated measures analysis of the primary endpoint was used to obtain a least squares mean estimate (LS mean) of the magnitude of the treatment effect. The LS mean change in percent predicted FVC at Week 72 was -6.5% and -9.6% in the pirfenidone and placebo groups, respectively, in CAPACITY 2, and -6.5% and -7.2%, respectively, in CAPACITY 1. This represents a relative reduction of 32% in CAPACITY 2 and 10% in CAPACITY 1.

To better understand the primary efficacy outcome, InterMune conducted a series of exploratory analyses interrogating the time course of treatment effect. An exploratory repeated measures analysis of ranked change from baseline, assessing treatment effect over the full duration of the study suggested pirfenidone reduced the decline in FVC in both studies (CAPACITY 2 p = 0.004 and CAPACITY 1 p = 0.001). In both studies, the magnitude of treatment effect generally was most pronounced in the
'/>"/>

SOURCE InterMune
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. InterMune to Present at J.P. Morgan Healthcare Conference
2. InterMune to Present at Deutsche Bank Biotech Boston Confab
3. InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
4. InterMune to Release Third Quarter 2008 Financial Results on November 6
5. InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
6. InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
7. InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
8. InterMune to Present at Canaccord Adams Conference
9. InterMune Reports Second Quarter 2008 Financial Results and Business Highlights
10. InterMune to Present at BMO Healthcare Conference
11. InterMune to Release Second Quarter 2008 Financial Results and Provide Business Update on July 31
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... W. R. Grace & Co. ... Worms, Germany has received good manufacturing practice (GMP) ... International Pharmaceutical Excipient Council (IPEC) Foundation. ... SYLOID® FP brand of pharmaceutical grade excipient silica ... Curtis Bay, Maryland (USA) and Sorocaba, Brazil locations. ...
(Date:5/21/2015)... 2015  CytRx Corporation (NASDAQ: CYTR ), ... oncology, today announced positive updated results from its ... the treatment of unresectable glioblastoma multiforme (GBM), a ... trial is designed to investigate the preliminary efficacy ... have progressed following prior treatment with surgery, radiation ...
(Date:5/21/2015)... Research and Markets ( http://www.researchandmarkets.com/research/84975r/2015_global ... "2015 Global Survey on Flow Cytometry Adoption Trends" ... primary goal of this research is to analyze ... Key information the survey seeks to collect include ... predominantly used applications for flow cytometers, respondents, most ...
(Date:5/21/2015)... Kingston, Ontario (PRWEB) May 21, 2015 ... entered into an exclusive North American distribution agreement ... microbiology testing system. , With more than 160 ... of products and services for laboratory and production ... choice, operational excellence and differentiated services to enable ...
Breaking Biology Technology:Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Global Survey on Flow Cytometry Adoption Trends 2015 2Veolia’s TECTA™ B16 Instrument for E. Coli Detection is Offered Exclusively Through VWR 2
... ... engineering consulting firm Full Spectrum Software announces key hire. Cindy Larkin has been ... and software experience to her new role. , ... Southborough, MA (Vocus) November 3, 2009 -- Leading medical ...
... RIVER, N.J., Nov. 2 PDI, Inc. (Nasdaq: ... support to U.S. health care companies, and Physicians Interactive, ... and marketing services to life sciences companies, have entered ... first integrated network of digital sales and marketing solutions. ...
... 2 The World Egg Bank ... to infertile women, announced a first-of-its-kind partnership with a European ... fertilization (IVF) of donated frozen eggs at or less ... The exclusive partnership is between TWEB and IVI in Alicante, ...
Cached Biology Technology:Medical Device Software Engineering Firm Full Spectrum Software Appoints Cindy Larkin to Director of Client Services 2PDI and Physicians Interactive Partner To Provide Integrated, Personal and Digital Solutions to Life Sciences Companies 2PDI and Physicians Interactive Partner To Provide Integrated, Personal and Digital Solutions to Life Sciences Companies 3World Egg Bank Launches Medical Tourism Program With World's Largest Egg-Donation Fertility Clinic 2
(Date:5/19/2015)... May 19, 2015 ... the addition of the  "Genetic Testing Market ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent report, Genetic ... analysis of the current and future genetic ... tests, their working principles and types are ...
(Date:5/11/2015)... , May 11, 2015  Through a well-rounded UAS delegation ... had a strong showing at AUVSI,s Unmanned 2015 conference ... of Ohio,s UAS industry met with ... from all points along the UAS ecosystem. ... (DDC) Vice President for Aerospace Rich Knoll . "If ...
(Date:5/6/2015)... May 6, 2015 LifeBEAM, a developer of ... producer, announced today that they will expand their partnership ... first bio-sensing cycling helmet and the first joint project ... new colors in order to give cyclists more style ... addition, LifeBEAM and Lazer announced their plan to release ...
Breaking Biology News(10 mins):Global Genetic Testing Market Outlook 2018 2Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3
... Who of bats, bears, beaked whales and all of Earth,s ... a Field Museum scientific team with access to one of ... team headed by the IUCN (International Union for Conservation of ... including assessments of diversity, threat and knowledge of the creatures. ...
... MADISON, WI, October 1, 2008 - As a nutrient, ... and potassium, but a new book explains its crucial ... agricultural professionals, understanding how plants use sulfur is essential ... A Missing Link Between Soils, Crops and Nutrition , ...
... What: To stop cancer before it has a ... turning their attention to new discoveries in cancer prevention. ... share the latest research in this expanding and promising ... reduce cancer incidence and mortality. To help you ...
Cached Biology News:Field Museum provides gold standard for mammal survey 2Field Museum provides gold standard for mammal survey 3
... pathway studies, protein-protein interaction studies, and ... on the flexible and powerful Paraflo ... are available as part of our ... Custom Probe Content Probe ...
... Arrays are intended for laboratory research use ... in neutral buffered formalin and embedded in ... performed by certified pathologists. Tissue cores ... relocated into a new recipient paraffin block, ...
... Mega Western Protein Array was developed using ... Protein Arrays are manufactured using high quality ... A protein sample from each of 30 ... Protein molecular weight marker on a large ...
... Using the New FAST(tm) Frame Multi-Slide Plate! ... designed to hold four, 16-pad FAST Slides ... a microplate footprint for high throughput processing ... standards recommended by the Society of Biomolecular ...
Biology Products: